Scalable iPSC-derived organoid screening for drug discovery
Human-relevant, standardized preclinical models
Organoid platforms for biotech and pharmaceutical R&D
OrganoVista Biosciences develops scalable organoid-based screening solutions to improve the predictability of early drug discovery.
Our approach combines standardized iPSC-derived organoids, high-content imaging and phenotypic analytics to help biotech and pharmaceutical teams evaluate compound efficacy and toxicity earlier and more reliably.
Standardized Human Biology
Non-patient-derived iPSC organoids with controlled differentiation and reproducible phenotypes.
High-Content Phenotypic Analysis
Multiparametric imaging and data-driven phenotype profiling for early discovery decisions.
OrganoVista’s platform integrates standardized iPSC-derived organoids with automated screening workflows and high-content phenotypic analysis.
The platform is designed for scalability, reproducibility and compatibility with preclinical research requirements, without the use of patient-derived biological material.
Organoid-based phenotypic screening platform
iPSC
Organoids
Screening
Phenotypes
Insights
Core Technologies
iPSC-Derived Organoids
Uniform, non-patient-derived organoid models generated under controlled differentiation protocols
CRISPR-Enabled Disease Modeling
Genetically engineered iPSC lines for reproducible disease-relevant phenotype
High-Content Imaging
Uniform, non-patient-derived organoid models generated under controlled differentiation protocols
Phenotypic Analytics
Image-based feature extraction and phenotype clustering for compound profiling
Services
Screening Campaigns
Organoid-based drug screening campaigns designed for preclinical and early discovery research.
Clients submit compound libraries that are screened on standardized organoid models using high-content phenotypic analysis.
Deliverables include structured research-use-only reports covering efficacy, toxicity and phenotype profiles
Assay Expansion Program
Continuous access to newly validated biological readouts and expanded assay configurations.
You will get benefit from ongoing improvements in phenotypic depth and assay content across all screening campaigns executed during the subscription period
Reference Phenotype Program
Access to curated, aggregated reference phenotypic datasets generated from standardized organoid models.
Designed to support benchmarking and interpretation of screening results
Traditional 2D systems oversimplify human biology and often fail to predict clinical outcomes.
We provide structured 3D organoid models that capture tissue-level phenotypes
We provide structured 3D organoid models that capture tissue-level phenotypes
Our managers are always ready to answer your questions. You can call us during the weekends and at night. Also, you can visit our office for a personal consultation.
Our company works according to the principle of individual approach to every client. This method allows us to succeed in tasks of any level.
Publications & Technical Documents
OrganoVista Biosciences actively develops and documents its scientific and technological approach
Recent researches:
iPSC-Derived Organoids and AI-Driven Phenotypic Screening for Preclinical Drug Discovery
Advantages of Non-Patient-Derived Organoid Systems for Scalable Pharmaceutical Workflows
All materials are provided for informational and research purposes only.
OrganoVista Biosciences operates exclusively within a research-use-only (RUO) framework
Key principles:
- No patient-derived biological materials
- No clinical or diagnostic services
- No long-term storage of biological samples
- BSL-2 laboratory operations
- Compliance with EU research and biosafety standards
All services are intended for preclinical research and drug discovery support only.
Sing Up
Just type your contacts
